{"id":"cmab007","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While the exact molecular target of CMAB007 has not been publicly disclosed in detail, it is developed as an immunotherapeutic monoclonal antibody by Taizhou Mabtech Pharmaceutical. As a Phase 3 candidate, it is likely designed to modulate immune responses against cancer cells, potentially through checkpoint inhibition or direct tumor antigen targeting.","oneSentence":"CMAB007 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:29.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07246252","phase":"PHASE1","title":"Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2024-03-28","conditions":"Healthy Volunteers (HV)","enrollment":114},{"nctId":"NCT06365879","phase":"PHASE3","title":"To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria","status":"RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2024-06-18","conditions":"Chronic Spontaneous Urticaria","enrollment":392},{"nctId":"NCT06398652","phase":"PHASE3","title":"Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2024-08-27","conditions":"Psoriasis","enrollment":336},{"nctId":"NCT05897008","phase":"PHASE1","title":"The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity","status":"COMPLETED","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2022-02-07","conditions":"Healthy Volunteers","enrollment":114},{"nctId":"NCT04778137","phase":"PHASE1","title":"The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety","status":"COMPLETED","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2020-12-01","conditions":"Asthma","enrollment":114},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Omalizumab alpha","recombinant humanized anti-IgE monoclonal antibody"],"phase":"phase_3","status":"active","brandName":"CMAB007","genericName":"CMAB007","companyName":"Taizhou Mabtech Pharmaceutical Co.,Ltd","companyId":"taizhou-mabtech-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}